Trospium Chloride
Brand names: Trospium Chloride, Trospium Chloride Er
At a glance
- Medicare prescriptions, 2024
- 391,679
- Medicare drug cost
- $29.2M
- Average cost per prescription
- $74.68
- Clinicians who prescribed it
- 10,531
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
Trospium Chloride Extended-Release Capsules are a muscarinic antagonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency.
From the FDA-approved prescribing information (label dated November 2022). Full labels on DailyMed (opens in a new tab)
Who prescribes it
- Urology 36.3%
- Nurse Practitioners 18.8%
- Physician Assistants 14.9%
- Urogynecology 8.2%
- Family Medicine 8.2%
- Internal Medicine 8.0%
- OB-GYN (Obstetrics & Gynecology) 2.9%
- Geriatric Medicine 1.1%
- Neurology 0.4%
- Hospitalist 0.2%
- General Practice 0.2%
- Certified Nurse-Midwives 0.1%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions rose 69% from 2019 to 2024.
Biggest change by state since 2019
- Virginia +179%
- North Carolina +178%
- Florida +108%
- Washington +101%
- Texas +91%
- Colorado (smallest change) −1%
- California (smallest change) +19%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 5 makers on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
American Health PAckaging
| Strength | Looks like | Imprint |
|---|---|---|
| 20 mg | yellow round tablet, 6 mm | L 1 |
Bryant Ranch Prepack
| Strength | Looks like | Imprint |
|---|---|---|
| 60 mg | white capsule, 20 mm | PAD 0118 |
Granules Pharmaceuticals Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 60 mg | orange capsule, 22 mm | G60 027 |
Padagis US LLC
| Strength | Looks like | Imprint |
|---|---|---|
| 60 mg | white capsule, 20 mm | PAD 0118 |
Pd-Rx Pharmaceuticals, Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 20 mg | white round tablet, 4 mm | PAD 145 |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
No industry payments to clinicians named this drug in 2025.
Recalls and shortages
Not on the FDA drug shortage list.
1 recall since 2020
- Oct 2023 · Padagis US LLC · Class II
Failed Tablets/Capsules specifications; missing/broken/extra tablets within the capsules
Recalls usually affect specific lots from one maker, not every version of a drug. Class I is the most serious; most drug recalls are Class II. FDA recalls (opens in a new tab)
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.